Preclinical CRO Market by Services, Application, End-User

Description

List of Tables

The Global Preclinical CRO Market is forecasted to grow significantly, with a projected USD 5,830.80 million in 2023 at a CAGR of 9.65% and expected to reach a staggering USD 11,137.65 million by 2030.

The the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Preclinical CRO Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Preclinical CRO Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Services, market is studied across Bioanalysis & DMPK Studies and Toxicology Testing. The Bioanalysis & DMPK Studies commanded largest market share of 43.84% in 2022, followed by Toxicology Testing.

Based on Application, market is studied across Cardiovascular Disease, Dermatology, Gastrointestinal, Genitourinary & Women's Health, Hematology, Immunological Disorders, Infectious Diseases, Metabolic Disorders, Neurology, Oncology, Ophthalmology, and Respiratory Disorders. The Oncology commanded largest market share of 13.21% in 2022, followed by Immunological Disorders.

Based on End-User, market is studied across Biopharmaceutical Companies, Government & Academic Institutes, and Medical Device Companies. The Biopharmaceutical Companies commanded largest market share of 66.13% in 2022, followed by Medical Device Companies.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 40.50% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Preclinical CRO Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Preclinical CRO Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Preclinical CRO Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Preclinical CRO Market?

4. What is the competitive strategic window for opportunities in the Global Preclinical CRO Market?

5. What are the technology trends and regulatory frameworks in the Global Preclinical CRO Market?

6. What is the market share of the leading vendors in the Global Preclinical CRO Market?

7. What modes and strategic moves are considered suitable for entering the Global Preclinical CRO Market?

Product Code: MRR-A339DAEFA52E

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Preclinical CRO Market, by Services, 2022 vs 2030
4.3. Preclinical CRO Market, by Application, 2022 vs 2030
4.4. Preclinical CRO Market, by End-User, 2022 vs 2030
4.5. Preclinical CRO Market, by Region, 2022 vs 2030

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Increasing R&D activities by pharmaceutical and biopharmaceutical companies to develop new drugs & therapies
  - 5.1.1.2. Rising trend of outsourcing drug development activities to CROs by pharmaceutical companies
  - 5.1.1.3. Growing focus on the development of personalized medicines
- 5.1.2. Restraints
  - 5.1.2.1. High cost and time-consuming constraints associated with preclinical CRO services
- 5.1.3. Opportunities
  - 5.1.3.1. Growing advances in technologies to enable more efficient and cost-effective preclinical research
  - 5.1.3.2. High potential for preclinical research for biologics, including monoclonal antibodies, vaccines, and cell therapies
- 5.1.4. Challenges
  - 5.1.4.1. Stringent regulations and guidelines set by international regulatory authorities
5.2. Market Trends
- 5.2.1. Presence of well-established pharmaceutical & biopharmaceutical companies and the rising introduction of advanced preclinical CRO platforms in the Americas
- 5.2.2. Rising government support for expanding research & development activities into developing new drugs and medical devices in the Asia-Pacific region
- 5.2.3. Potential government funding in drug development activities expands the preclinical CRO business in the EMEA region.
5.3. Cumulative Impact of COVID-19
5.4. Cumulative Impact of Russia-Ukraine Conflict
5.5. Cumulative Impact of High Inflation
5.6. Porter's Five Forces Analysis
- 5.6.1. Threat of New Entrants
- 5.6.2. Threat of Substitutes
- 5.6.3. Bargaining Power of Customers
- 5.6.4. Bargaining Power of Suppliers
- 5.6.5. Industry Rivalry
5.7. Value Chain & Critical Path Analysis
5.8. Regulatory Framework
5.9. Client Customization

6. Preclinical CRO Market, by Services

6.1. Introduction
6.2. Bioanalysis & DMPK Studies
6.3. Toxicology Testing

7. Preclinical CRO Market, by Application

7.1. Introduction
7.2. Cardiovascular Disease
7.3. Dermatology
7.4. Gastrointestinal
7.5. Genitourinary & Women's Health
7.6. Hematology
7.7. Immunological Disorders
7.8. Infectious Diseases
7.9. Metabolic Disorders
7.10. Neurology
7.11. Oncology
7.12. Ophthalmology
7.13. Respiratory Disorders

8. Preclinical CRO Market, by End-User

8.1. Introduction
8.2. Biopharmaceutical Companies
8.3. Government & Academic Institutes
8.4. Medical Device Companies

9. Americas Preclinical CRO Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Preclinical CRO Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Preclinical CRO Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
- 12.3.1. Merger & Acquisition
  - 12.3.1.1. AmplifyBio Expands Cell Therapy Characterization, Fills Gap in Preclinical Development
  - 12.3.1.2. Clinchoice Continues Expansion with CRO Acquisition
  - 12.3.1.3. CRO Avania Acquires MAXIS
  - 12.3.1.4. Apax Acquires a Majority Stake in Porsolt to Support its Growth Strategy and Become a Global Leader in Preclinical Services
- 12.3.2. Agreement, Collaboration, & Partnership
  - 12.3.2.1. Cryoport Announces Strategic Partnership with Syneos Health to Advance Cell & Gene Therapies
  - 12.3.2.2. Crown Bioscience and ERS Genomics Announce Global CRISPR/Cas9 Licensing Agreement for Genome Editing Patents
  - 12.3.2.3. Domain Therapeutics and Explicyte Enter Partnership Agreement in Immuno-Oncology
  - 12.3.2.4. Hera BioLabs Announces Exclusive Global License With Charles River
  - 12.3.2.5. IonsGate Preclinical Services and InSilicoTrials Form Partnership
- 12.3.3. New Product Launch & Enhancement
  - 12.3.3.1. PsychoGenics Launches eCube, a New AI-Enabled Platform for Drug Discovery
- 12.3.4. Investment & Funding
  - 12.3.4.1. CRO Company TriApex Completes Series C Financing Round Led by Legend Capital
  - 12.3.4.2. ClinChoice Raises USD 150 Million in Series E Round
- 12.3.5. Award, Recognition, & Expansion
  - 12.3.5.1. Proscia Announces Major Expansion in Preclinical R&D to Drive Faster Drug Safety Decisions
  - 12.3.5.2. QPS opens an additional preclinical research facility in Taiwan
  - 12.3.5.3. Celerion Expands Early Phase Clinical Pharmacology Units

13. List of Company Mentioned

14. Appendix

14.1. Discussion Guide
14.2. License & Pricing

1. 10x Genomics, Inc.

2. AmplifyBio

3. Atuka Inc.

4. BenchSci

5. Bioserve Biotechnologies (India) PVT Ltd. by REPROCELL Inc.

6. Biotrofix, Inc.

7. Celerion

8. Charles River Laboratories International, Inc.

9. Crown Bioscience, Inc.

10. CTI Clinical Trial and Consulting, Inc.

11. Diag2Tec SAS

12. Eurofins Scientific SE

13. F. Hoffmann-La Roche Ltd.

14. Gubra

15. Hera Biolabs

16. ICON PLC

17. Immusmol SAS

18. ImQuest BioSciences

19. Inotiv, Inc.

20. Intertek Group PLC

21. Invivotek by Genesis Biotechnology Group, LLC

22. IQVIA Inc.

23. Jubilant Biosys Ltd. byJubilant Pharmova Limited Company

24. Laboratory Corporation of America Holding

25. MCI Group Holding SA

26. MD Biosciences

27. Medpace Holdings, Inc.

28. Novartis AG

29. Parexel International Corporation.

30. PharmaCircle LLC

31. Phenos GmbH

32. PPD by Thermo Fisher Scientific Inc.

33. PsychoGenics Inc.

34. QPS Holdings, LLC

35. Sanofi S.A.

36. SCiAN Services Inc.

37. SGS SA

38. Shanghai Medicilon Inc.

39. Syneos Health, Inc.

40. Transpharmation

41. Veristat, LLC

42. Vimta Labs Limited

43. WuXi AppTec Co., Ltd.